Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly FCF Margin of 1166.08% in Q1 2026, up 27.14% quarter-over-quarter from 1600.49% in Q4 2025, and up 2340899.0% on a YoY basis from N/an in Q1 2025.
Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' FCF Margin history runs 10 years deep, the most recent figure standing at 1166.08% for Q1 2026.
- In Q1 2026, FCF Margin rose 2340899.0% year-over-year to 1166.08%; the TTM figure through Mar 2026 stood at 2325.17% (up 3316562.0% YoY), while the FY2025 annual figure was 4985.5%, up 1753981.0% from the prior year.
- FCF Margin was 1166.08% for Q1 2026 at Crinetics Pharmaceuticals, up from 1600.49% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 435.32% in Q1 2022 to a low of 74359.44% in Q3 2025.
- Historically, FCF Margin has averaged 12194.51% across 5 years, with a median of 7387.05% in 2022.
- The sharpest annual moves came in 2025 and 2026: FCF Margin plunged 1629007 bps in 2025, then soared 2340899 bps in 2026.
- A 5-year view of FCF Margin shows it stood at 5190.83% in 2022, then sank by 150 bps to 12959.25% in 2023, then grew by 4 bps to 12471.93% in 2024, then soared by 87 bps to 1600.49% in 2025, then grew by 27 bps to 1166.08% in 2026.
- The last three FCF Margin figures came in at 1166.08% (Q1 2026), 1600.49% (Q4 2025), and 74359.44% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | -1,166.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,166.08% |
| Dec 31, 2025 | -1,600.49% |
| Sep 30, 2025 | -74,359.44% |
| Jun 30, 2025 | -8,732.10% |
| Mar 31, 2025 | -24,575.07% |
| Jun 30, 2024 | -12,471.93% |
| Mar 31, 2024 | -8,285.00% |
| Sep 30, 2023 | -12,959.25% |
| Jun 30, 2023 | -4,653.04% |
| Mar 31, 2023 | -1,520.49% |
| Dec 31, 2022 | -5,190.83% |
| Sep 30, 2022 | -8,261.79% |
| Jun 30, 2022 | -6,512.30% |
| Mar 31, 2022 | -435.32% |
| Dec 31, 2021 | -2,125.88% |
| Dec 31, 2020 | 22,471.83% |
| Mar 31, 2020 | -17,309.86% |
| Dec 31, 2019 | -4,079.44% |
| Sep 30, 2019 | -2,694.46% |
| Mar 31, 2019 | -1,952.86% |